Filing Summary
Business Context and Reporting Period
This Form 6-K was furnished by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for December 2023 (Report No. 2), and was signed on December 4, 2023. The filing concerns an extraordinary shareholders’ meeting scheduled for December 22, 2023.
The request metadata identifies the company as Newcelx Ltd.; however, the filing itself identifies the registrant as NLS Pharmaceutics Ltd. Investors should verify the applicable issuer identity.
Meeting and Corporate Actions
- The filing includes the Notice of Meeting and Proxy Card for the December 22, 2023 shareholders’ meeting.
- Only shareholders of record holding common shares at the close of business on November 23, 2023 were entitled to vote, including at any postponement or adjournment.
- The filing does not provide the specific proposals or voting recommendations contained in the attached proxy materials.
- The report is incorporated by reference into the registrant’s specified Form F-3 registration statements, subject to later filings.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, operating results, or other financial metrics.
Outlook, Risks, and Unusual Items
The filing does not provide financial guidance, business outlook, management commentary, risk disclosures, contingencies, or unusual financial items. Its principal disclosure is the notice of the upcoming shareholders’ meeting.
Important Facts to Verify
- Confirm whether NLS Pharmaceutics Ltd. or Newcelx Ltd. is the intended company for this summary.
- Review Exhibit 99.1 to identify the meeting proposals, voting thresholds, and management recommendations.
- Verify the outcome of the December 22, 2023 meeting and any subsequent adjournments or related filings.
- Consult the company’s periodic financial reports for current financial performance and liquidity information.